Trial Purpose

In this study, participants with high-risk non-muscle-invasive bladder cancer (NMIBC) unresponsive to Bacillus Calmette Guerin (BCG) therapy and who are considered ineligible for or have refused to undergo radical cystectomy, will receive pembrolizumab therapy or pembrolizumab in combination with other investigational agents. The primary study hypothesis is that treatment with pembrolizumab will result in a clinically meaningful response.

Learn More on ClinicalTrials.gov

CLINICALTRIALS.GOV IDENTIFIER:

NCT02625961

When speaking to your doctor, please have the trial identifier number available.

About The Study

100% will receive pembrolizumab only

Trial Phase Icon

Phase 2

Tests the medicine or vaccine in approximately 100 to 500 volunteers. In the case of medicines, volunteers usually have the disease or condition the investigational medicine is designed to treat. In vaccine studies, the volunteers are usually healthy.

Trial start Icon

Dates

  • Actual study start date 10 February 2016
  • Estimated primary completion date 30 August 2026
  • Estimated study completion date 31 August 2030

Eligibility

Only a qualified healthcare professional can determine your eligibility. However, this information may be useful in starting a conversation with your doctor.

Conditions Icon

Conditions

Bladder Cancer

Age Range Icon

Age Range

18 - No Age Maximum

Sex Icon

Sex

All

Trial locations

Locations provided may not reflect the most current site information. Please call the number provided in the location results to confirm.